Expression of the endocannabinoid system in fibroblasts and myofascial tissues

Journal of Bodywork and Movement Therapies

Volumn 12, Issue 2, 2008, Pages 169-182

  McPartland, John M ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Ajulemic acid; Biodynamics; Cannabinoids; Chiropractic; Endocannabinoids; Fibromyalgia; Myofascial release; Myofascial trigger points; Osteopathic medicine

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYTOKINE; ENDOCANNABINOID; METALLOPROTEINASE;

ARTICLE; BIOINFORMATICS; CARTILAGE CELL; DIET THERAPY; EMBRYO DEVELOPMENT; FASCIA; FIBROBLAST; FIBROMYALGIA; FUNCTIONAL PROTEOMICS; INFLAMMATION; LIFESTYLE; MANIPULATIVE MEDICINE; MYOFASCIAL PAIN; MYOFIBROBLAST; NOCICEPTION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SYNOVIOCYTE; TISSUE DISTRIBUTION; TRIGGER POINT;

ANIMALS; COMPUTATIONAL BIOLOGY; ENDOCANNABINOIDS; FIBROBLASTS; HUMANS; MYOFASCIAL PAIN SYNDROMES; NOCICEPTORS; RECEPTORS, CANNABINOID;

EID: 40949145644     PISSN: 13608592     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbmt.2008.01.004     Document Type: Article

References (89)

1. Abe M., Sogabe Y., Syuto T., Yokoyama Y., and Ishikawa O. Evidence that PI3K, Rac, Rho and Rho kinase are involved in basic fibroblast growth factor-stimulated fibroblast-collagen matrix contraction. Journal of Cellular Biochemistry 102 (2007) 1290
2. Agarwal N., Pacher P., Tegeder I., Amaya F., Constantin C.E., Brenner G.J., Rubino T., Michalski C.W., Marsicano G., Monory K., Mackie K., Marian C., Batkai S., Parolaro D., Fischer MJ., Reeh P., Kunos G., Kress M., Lutz B., Woolf CJ., and Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nature Neuroscience 10 (2007) 870-879
3. Aguado T., Romero E., Monory K., Palazuelos J., Sendtner M., Marsicano G., Lutz B., Guzman M., and Galve-Roperh I. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. Journal of Biological Chemistry 282 (2007) 23892-23898
4. Ashton JC. Cannabinoids for the treatment of inflammation. Current Opinion in Investigational Drugs 8 (2007) 373-384
5. Ashton JC., Appleton I., Darlington CL., and Smith PF. Cannabinoid CB1 receptor protein expression in the rat choroid plexus: a possible involvement of cannabinoids in the regulation of cerebrospinal fluid. Neuroscience Letters 364 (2004) 40-42
6. Bari M., Oddi S., De Simone C., Spagnolo P., Gasperi V., Battista N., Centonze D., and Maccarrone M. Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. Neuropharmacology 54 (2007) 45-50
7. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand JP., Le Fur G., Oury-Donat F., and Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular Pharmacology 63 (2003) 908-914
8. Berger, A., Crozier, G., Bisogno, T., Cavaliere, P., Innis, S., Di Marzo, V., 2001. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proceedings of the National Academy of Sciences of the United States of America 98, 6402-6406.
9. Berghuis P., Rajnicek AM., Morozov YM., Ross RA., Mulder J., Urbán GM., Monory K., Marsicano G., Matteoli M., Canty A., Irving AJ., Katona I., Yanagawa Y., Rakic P., Lutz B., Mackie K., and Harkany T. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 316 (2007) 1212-1216
10. Blechschmidt E. Beginnings of Human Life (1977), Springer, Berlin
11. Crystal J.D., Maxwell K.W., and Hohmann AG. Cannabinoid modulation of sensitivity to time. Behaviour and Brain Research 144 (2003) 57-66
12. Curtis MA., Faull RL., and Glass M. A novel population of the progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. Journal of Chemical Neuroanatomy 31 (2006) 210-215
13. Degenhardt BF., Darmani NA., Johnson JC., Towns LC., Rhodes DC., Trinh C., McClanahan B., and DiMarzo V. Role of osteopathic manipulative treatment in altering pain biomarkers: a pilot study. Journal of the American Osteopathic Association 107 (2007) 387-394
14. Dickson BJ. Molecular mechanisms of axon guidance. Science 298 (2002) 1959-1964
15. Dietrich A., and McDaniel WF. Endocannabinoids and exercise. British Journal of Sports Medicine 38 (2004) 536-541
16. Dodd JG., Good MM., Nguyen TL., Grigg AI., Batia LM., and Standley PR. In vitro biophysical strain model for understanding mechanisms of osteopathic manipulative treatment. Journal of the American Osteopathic Association 106 (2006) 157-166
17. Dossey L. PEAR Lab and Nonlocal Mind: Why They Matter (2007), Explore, New York pp.191-196
18. Dunnett AJ., Roy D., Stewart A., and McPartland JM. The diagnosis of fibromyalgia in women may be influenced by menstrual cycle phase. Journal of Bodywork and Movement Therapies 11 (2007) 99-105
19. Emboden WA. Adaptogens: a new formula for health?. Osteopathic Physician 73 8 (1976) 68-73
20. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Janke J., Batkai S., Pacher P., Harvey-White J., Luft FC., Sharma AM., and Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005) 2838-2843
21. Food and Drug Administration. FDA Briefing Document: New Drug Application 21-888. Zimulti (rimonabant) (2007), Food and Drug Administration, Washington, DC. http://www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4306b1-fda-backgrounder.pdf Available at: 〈www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4306b1-fda-backgrounder.pdf〉
22. Fowler CJ. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. Trends in Pharmacological Science 25 (2004) 59-61
23. Frazer KA., Elnitski L., Church DM., Dubchak I., and Hardison RC. Cross-species sequence comparisons: a review of methods and available resources. Genome Research 13 (2003) 1-12
24. In: Freeman B. (Ed). The Ontogenetic Basis of Human Anatomy, by Erich Blechschmidt (2004), North Atlantic Books, Berkeley, CA
25. Fride E. The endocannabinoid-CB(1) receptor system in pre- and postnatal life. European Journal of Pharmacology 500 (2004) 289-297
26. Galarreta M., Erdelyi F., Szabo G., and Hestrin S. Electrical coupling among irregular-spiking GABAergic interneurons expressing cannabinoid receptors. Journal of Neuroscience 24 (2004) 9770-9778
27. Gasperi V., Fezza F., Pasquariello N., Bari M., Oddi S., Agro AF., and Maccarrone M. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cellular and Molecular Life Sciences 64 (2007) 219-229
28. Gaus K., Le Lay S., Balasubramanian N., and Schwartz MA. Integrin-mediated adhesion regulates membrane order. Journal of Cellular Biology 174 (2006) 725-734
29. Giuffrida A., Leweke FM., Gerth CW., Schreiber D., Koethe D., Faulhaber J., Klosterkötter J., and Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29 (2004) 2108-2114
30. Gokoh M., Kishimoto S., Oka S., Mori M., Waku K., Ishima Y., and Sugiura T. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. Biochemical Journal 386 (2005) 583-589
31. Gonzalez S., Cascio MG., Fernandez-Ruiz J., Fezza F., Di Marzo V., and Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Research 954 (2002) 73-81
32. Guzman M. Cannabinoids: potential anticancer agents. Nature Reviews Cancer 3 (2003) 745-755
33. Harbach H., Moll B., Boedeker RH., Vigelius-Rauch U., Otto H., Muehling J., Hempelmann G., and Markart P. Minimal immunoreactive plasma beta-endorphin and decrease of cortisol at standard analgesia or different acupuncture techniques. European Journal of Anaesthesiology 24 (2007) 370-376
34. He F., and Song ZH. Molecular and cellular changes induced by the activation of CB2 cannabinoid receptors in trabecular meshwork cells. Molecular Vision 13 (2007) 1348-1356
35. Hill MN., Patel S., Carrier EJ., Rademacher DJ., Ormerod BK., Hillard CJ., and Gorzalka BB. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30 (2005) 508-515
36. Hill MN., Ho WS., Sinopoli KJ., Viau V., Hillard CJ., and Gorzalka BB. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31 (2006) 2591-2599
37. Högestatt ED., Jonsson BA., Ermund A., Andersson DA., Bjork H., Alexander JP., Cravatt BF., Basbaum AI., and Zygmunt PM. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. Journal of Biological Chemistry 280 (2005) 31405-31412
38. Hohmann AG., and Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92 (1999) 1171-1175
39. Howlett AC., Barth F., Bonner TI., Cabral G., Casellas P., Devane WA., Felder CC., Herkenham M., Mackie K., Martin BR., Mechoulam R., and Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 54 (2002) 161-202
40. Ingber D. In search of cellular control: signal transduction in context. Journal of Cellular Biochemistry Supplement 30-31 (1998) 232-237
41. Johnson D.R., Stebulis J.A., Rossetti R.G., Burstein S.H., and Zurier R.B. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. Journal of Cellular Biochemistry 100 (2007) 184-190
42. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews Immunology 5 (2005) 400-411
43. Koeberle P.D., and Bahr M. Growth and guidance cues for regenerating axons: where have they gone?. Journal of Neurobiology 59 (2004) 162-180
44. Langevin H.M., Bouffard N.A., Badger G.J., Churchill D.L., and Howe A.K. Subcutaneous tissue fibroblast cytoskeletal remodeling induced by acupuncture: evidence for a mechanotransduction-based mechanism. Journal of Cellular Physiology 207 (2006) 767-774
45. Li J.J., Chen R.M., Liu L., Wang S.Y., Yu P., Xie Y., Li M., and Shi J. Effects of electroacupuncture on the immunoreactivity of focal cutaneous CB2 receptor positive cells in arthritis rats. Zhen Ci Yan Jiu 32 (2007) 9-15
46. Mancall A.C., DiGregorio G.J., Brill C.B., and Ruch E. The effect of delta-9-tetrahydrocannabinol on rat cerebrospinal fluid. Archives of Neurology 42 (1985) 1069-1071
47. Martin M., Ledent C., Parmentier M., Maldonado R., and Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159 (2002) 379-387
48. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., Pagotto U., Monteleone P., and Di Marzo V. Regulation, function and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. Journal of Clinical Endocrinology and Metabolism 91 (2006) 3171-3180
49. Matias I., and Di Marzo V. Endocannabinoids and the control of energy balance. Trends in Endocrinology and Metabolism 18 (2007) 27-37
50. Mátyás F., Urbán GM., Watanabe M., Mackie K., Zimmer A., Freund T.F., and Katona I. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 54 (2007) 95-107
51. Mbvundula E.C., Bunning R.A., and Rainsford K.D. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochemical Pharmacology 69 (2005) 635-640
52. McPartland J.M., and Guy G. The evolution of Cannabis and coevolution with the cannabinoid receptor-a hypothesis. In: Guy G., Robson R., Strong K., and Whittle B. (Eds). The Medicinal Use of Cannabis (2004), Royal Society of Pharmacists, London 71-102
53. McPartland J.M., and Simons D.G. Myofascial trigger points: translating molecular theory into manual therapy. Journal of Manual and Manipulative Therapies 14 (2007) 232-239
54. McPartland J.M., and Skinner E. The biodynamic model of osteopathy in the cranial field. Explore (NY) 1 1 (2005) 21-32
55. McPartland J.M., Giuffrida A., King J., Skinner E., Scotter J., and Musty R.E. Cannabimimetic effects of osteopathic manipulative treatment. Journal of the American Osteopathic Association 105 (2005) 283-291
56. McPartland J.M., Matias I., Di Marzo V., and Glass M. Evolutionary origins of the endocannabinoid system. Gene 370 (2006) 64-74
57. McPartland J.M., Norris R.W., and Kilpatrick C.W. Tempo and mode in the endocannabinoid system. Journal of Molecular Evolution 65 (2007) 267-276
58. Mechoulam R., Fride E., and Di Marzo V. Endocannabinoids. European Journal of Pharmacology 359 (1998) 1-18
59. Mense S., Simons DG., Hoheisel U., and Quenzer B. Lesions of rat skeletal muscle after local block of acetylcholinesterase and neuromuscular stimulation. Journal of Applied Physiology 94 (2003) 2494-2501
60. Newman S.A., Frenz D.A., Tomasek J.J., and Rabuzzi D.D. Matrix-driven translocation of cells and nonliving particles. Science 228 (1985) 885-889
61. Newman Z., Malik P., Wu T.Y., Ochoa C., Watsa N., and Lindgren C. Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction. European Journal of Neuroscience 25 (2007) 1619-1630
62. O'Leary D.S., Block R.I., Turner B.M., Koeppel J., Magnotta V.A., and Ponto L.B. Marijuana alters the human cerebellar clock. Neuroreport 14 (2003) 1145-1151
63. Oliva J.M., Uriguen L., Perez-Rial S., and Manzanares J. Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain. Neuropharmacology 49 (2005) 618-626
64. Ortiz S., Oliva J.M., Perez-Rial S., Palomo T., and Manzanares J. Chronic ethanol consumption regulates cannabinoid CB1 receptor gene expression in selected regions of rat brain. Alcohol and Alcoholism 39 (2004) 88-92
65. Oschman J.L. The electromagnetic environment: implications for bodywork: Part 2: Biological effects. Journal of Bodywork and Movement Therapies 4 2 (2000) 137-150
66. Pacher P., Bátkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 58 (2006) 389-462
67. Panagiotis M., Lloyd DH., Pfeiffer D., Stevens K., Auxilia S., Noli C., Abramo F., and Miolo A. Veterinary wounds: assessment of the effect of an aliamide-containing topical gel by evaluation of the reduction of wound volume measured by high-resolution ultrasound biomicroscopy. Wounds 19 5 (2007) 113-119
68. Park B., McPartland J.M., and Glass M. Cannabis, cannabinoids and reproduction. Prostaglandins, Leukotrienes and Essential Fatty Acids 70 (2004) 189-197
69. Pert C. Foreword. In: Oschman J.L. (Ed). Energy Medicine (2000), Churchill Livingstone, Edinburgh pp. ix-xi
70. Pertwee R.G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS Journal 7 (2005) E625-E654
71. Pevsner J. Leonardo da Vinci's contributions to neuroscience. Trends in Neuroscience 25 (2002) 217-220
72. Raduner S., Majewska A., Chen J.Z., Xie X.Q., Hamon J., Faller B., Altmann K.H., and Gertsch J. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. Journal of Biological Chemistry 281 (2006) 14192-14206
73. Rimmerman N., Hughes H.V., Bradshaw H.B., Pazos M.X., Mackie K., Prieto A.L., and Walker J.M. Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line. British Journal of Pharmacology 153 (2007) 380-389
74. Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., Dubuquoy C., Merour E., Geboes K., Chamaillard M., Ouwehand A., Leyer G., Carcano D., Colombel J.F., Ardid D., and Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature Medicine 13 (2007) 35-37
75. Russo E.B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuro Endocrinology Letters 25 (2004) 31-39
76. Sánchez-Pastor E., Trujillo X., Huerta M., and Andrade F. Effects of cannabinoids on synaptic transmission in the frog neuromuscular junction. Journal of Pharmacology and Experimental Therapeutics 321 2 (2007) 439-445
77. Sarnataro D., Grimaldi C., Pisanti S., Gazzerro P., Laezza C., Zurzolo C., and Bifulco M. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Letters 579 (2005) 6343-6349
78. Scutt A., and Williamson E.M. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcified Tissue International 80 (2007) 50-59
79. Shah J.P., Phillips T.M., Danoff J.V., and Gerber L.H. An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. Journal of Applied Physiology 99 (2005) 1977-1984
80. Sioutis J., Roussos N., Manoleas J., Patergianakis N., Charalabidis C., Karantonis G., and Lagogiannis N. The memory phenomenon and recurrent musculoskeletal pain. Spinal Cord Journal 42 Suppl. (2004) S163. http://www.iscos.org.uk/abstracts25.html Available at: 〈www.iscos.org.uk/abstracts25.html〉
81. Sparling P.B., Giuffrida A., Piomelli D., Rosskopf L., and Dietrich A. Exercise activates the endocannabinoid system. Neuroreport 14 (2003) 2209-2211
82. In: Sutherland W.G., Sutherland A.S., and Wales A. (Eds). Contributions of Thought, the Collected Writings of William Garner Sutherland (1967), Sutherland Cranial Teaching Foundation, Kansas City, MO
83. Vann R.E., Cook C.D., Martin B.R., and Wiley J.L. Cannabimimetic properties of ajulemic acid. Journal of Pharmacology and Experimental Therapeutics 320 (2007) 678-686
84. Ware M.A., Adams H., and Guy G.W. The medicinal use of cannabis in the UK: results of a nationwide survey. International Journal of Clinical Practice 59 (2005) 291-295
85. Watanabe S., Doshi M., and Hamazaki T. N-3 polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins, Leukotrienes and Essential Fatty Acids 69 (2003) 51-59
86. Williams E.J., Walsh F.S., and Doherty P. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. Journal of Cellular Biology 160 (2003) 481-486
87. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., and Bonner T.I. Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 5780-5785
88. Zou Y., Akazawa H., Qin Y., Sano M., Takano H., Minamino T., Makita N., Iwanaga K., Zhu W., Kudoh S., Toko H., Tamura K., Kihara M., Nagai T., Fukamizu A., Umemura S., Iiri T., Fujita T., and Komuro I. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nature Cell Biology 6 (2004) 499-506
89. Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., and Guimaraes F.S. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research 39 (2006) 421-429